Novartis AG has patented sphingosine 1-phosphate S1P3 receptor antagonists reported to be useful for the treatment of lung inflammation.

Tecnimede-Sociedade Tecnico-Medicinal SA has described heterocyclic compounds reported to be useful for the treatment of tuberculosis.

Astrazeneca AB and Mitsubishi Tanabe Pharma Corp. have divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of liver, autoimmune and inflammatory bowel disease, inflammation, respiratory, cardiovascular and renal disorders.

Janssen Pharmaceutica NV has identified 5-oxo-pyrido[2,3-d]pyridazin-6(5h)-yl acetamides acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, viral hepatitis, diabetes, immunological, inflammatory, neurological, cardiovascular and metabolic disorders.

Medshine Discovery Inc. has synthesized dimethyl-substituted thiazololactam compounds acting as mitogen-activated protein kinase 3 (MAPK3; ERK1) and/or (MAPK1; ERK2) inhibitors reported to be useful for the treatment of cancer.

Shanghai University of Traditional Chinese Medicine and Vestlandets Innovasjonsselskap AS (VIS) have disclosed bufalin derivatives acting as androgen receptor antagonists reported to be useful for the treatment of prostate cancer.

Dana-Farber Cancer Institute Inc. has described small-molecule GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Toray Industries Inc. has divulged aminocyclohexane derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of pain.

UCB SA has identified imidazotriazine derivatives acting as IL-17 modulators reported to be useful for the treatment of autoimmune and inflammatory disorders.

Medshine Discovery Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moieties covalently linked to bromodomain-containing protein 4 (BRD4; HUNK1) targeting moieties through a linker reported to be useful for the treatment of cancer.